|
|
|
Sunday, March 18, 2012 — 7:30 p.m. — Convention Centre 301-305
|
- Four "Ps" of Pulmonary Cytopathology: Procedural, Predictive, Personalized and Participatory
|
|
Moderator:
|
Dina R. Mody, The Methodist Hospital, Houston, TX
|
Click the button above to add this event to your Itinerary Planner...
| 7:30 |
Introduction of Program and Panelists: - Syed Z. Ali, The Johns Hopkins Hospital, Baltimore, MD |
| 7:50 |
Updates in the Surgical Pathology of Lung Cancer - William D. Travis, Memorial Sloan-Kettering Cancer Center, New York, NY |
| 8:25 |
Cytopathologic and Molecular Marker Analysis of Pulmonary Specimens - Fernando Schmitt, University of Porto, Portugal |
| 9:00 |
Management Guidelines and Targeted Therapies: An Oncologist's Perspective - Julie R. Brahmer, The Johns Hopkins Hospital, Baltimore, MD |
| 9:35 |
Role of Cytotechnologists in the Diagnosis and Management of Patients with Lung Cancer - Jill L. Caudill, Mayo School of Health Sciences, Rochester, MN |
| 10:10 | Question and Answer Session |
| The ASC routinely solicits topics of interest from its membership at the annual scientific meeting. The Scientific Program Committee assembled all such surveys and requests from our members and meeting attendees and discussed these topics at a special committee meeting in February, 2011 resulting in the program. In addition to numerous requests on diagnostic issues relating to cytomorphology, there was a huge interest for clinically-oriented lectures on molecular tools and targeted therapies. Cytopathology has rapidly evolved into a clinically-oriented discipline and plays a key role in timely and accurate patient management. Recent years have seen an exponential growth of newer techniques (automation, immunomarkers and various molecular tests) being applied to supplement morphologic evaluation of cytologic specimens. Lung cytology is a commonly practiced area in diagnostic cytopathology and offers a great example of how the new cutting edge molecular tests and targeted therapies offer a truly multidisciplinary approach in better managing patients with lung cancer. Additionally, the new International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma has created some confusion and unanswered questions particularly when dealing with small cytologic samples. |
|
|
|
